KR101127164B1 - Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri - Google Patents

Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri Download PDF

Info

Publication number
KR101127164B1
KR101127164B1 KR1020090087728A KR20090087728A KR101127164B1 KR 101127164 B1 KR101127164 B1 KR 101127164B1 KR 1020090087728 A KR1020090087728 A KR 1020090087728A KR 20090087728 A KR20090087728 A KR 20090087728A KR 101127164 B1 KR101127164 B1 KR 101127164B1
Authority
KR
South Korea
Prior art keywords
lactobacillus
glutaminase
gene
klb
seq
Prior art date
Application number
KR1020090087728A
Other languages
Korean (ko)
Other versions
KR20110029876A (en
Inventor
소재성
전정민
Original Assignee
인하대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인하대학교 산학협력단 filed Critical 인하대학교 산학협력단
Priority to KR1020090087728A priority Critical patent/KR101127164B1/en
Publication of KR20110029876A publication Critical patent/KR20110029876A/en
Application granted granted Critical
Publication of KR101127164B1 publication Critical patent/KR101127164B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20Synthetic spices, flavouring agents or condiments
    • A23L27/21Synthetic spices, flavouring agents or condiments containing amino acids
    • A23L27/22Synthetic spices, flavouring agents or condiments containing amino acids containing glutamic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • C12P13/14Glutamic acid; Glutamine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01002Glutaminase (3.5.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 락토바실러스 루테리의 글루타미나제 유전자가 도입되어 우수한 글루타미나제 활성을 가지는 락토바실러스 속 균주에 관한 것이다. The present invention relates to a strain of the genus Lactobacillus having a good glutaminase activity by introducing a glutaminase gene of Lactobacillus luterie.

본 발명에 의하여 높은 글루타미나제 활성을 가지는 락토바실러스 속 균주를 천연 식품 첨가제로 사용하여 글루타민으로부터 글루타민산염을 생산할 수 있으며, 이는 기존의 인공 식품 첨가제에 의한 부작용이나 병적 증세를 회피할 수 있다. According to the present invention, glutamate can be produced from glutamine by using a strain of the genus Lactobacillus having high glutaminase activity as a natural food additive, which can avoid side effects or pathological symptoms caused by existing artificial food additives.

글루타미나제, 락토바실러스, 형질전환 Glutaminase, Lactobacillus, Transformation

Description

락토바실러스 루테리의 글루타미나제 유전자가 도입된 락토바실러스 속 균주{Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri}Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri with the glutaminase gene of Lactobacillus luteri introduced

본 발명은 락토바실러스 루테리의 글루타미나제 유전자가 도입되어 우수한 글루타미나제 활성을 가지는 락토바실러스 속 균주에 관한 것이다. The present invention relates to a strain of the genus Lactobacillus having a good glutaminase activity by introducing a glutaminase gene of Lactobacillus luterie.

현재 각종 식품 첨가제로 화학조미료인 MSG(Monosodium glutamate; 모노소듐 글루타민산염)가 널리 사용되고 있으며, 그 소비량은 꾸준히 증가하고 있다. 그러나 화학적인 방법으로 합성한 MSG를 식품 첨가제로 사용하였을 때 경우에 따라 독성을 나타내기도 한다(Tiziana P et al.,Food Chemistry 104(4):1712-1717, 2007). 그리고 화학조미료(MSG)를 과다섭취함으로써, MSG에 민감한 사람들에게서 '중국 음식점 증후군(Chinese Restaurant Syndrome)', '암과의 관련성'(고온에서는 발암물질로 변할 수있음), '천식과의 관련성' 등이 나타난다고 보고된 바 있다. Currently, MSG (monosodium glutamate), a chemical seasoning, is widely used as a food additive, and its consumption is steadily increasing. However, chemically synthesized MSG is sometimes toxic when used as a food additive (Tiziana P et al., Food Chemistry 104 (4): 1712-1717, 2007). And by overingesting MSG, 'Chinese Restaurant Syndrome', 'Relevance to cancer' (which can turn into carcinogens at high temperatures), and 'Association with asthma' in people sensitive to MSG It has been reported to appear.

이에, 최근 식품 첨가제나 성분으로서 인체 내 건강에 이로움을 주는 천연 식품 첨가제에 대한 관심이 대두하고 있다. 식생활의 서구화에 따라 각종 성인병 발병의 주요 원인이 식생활에 있다는 것이 밝혀지면서 생명체(동물, 식물, 미생물)와 효소로부터 인체의 생리기능을 향상시키는 기능성 물질을 찾는 연구가 함께 이루어지고 있다. 그 중에서 음식의 맛을 증진시킬 수 있는 상업적으로 중요한 효소로 알려져 있는 글루타미나제(glutaminase) 효소를 대표적인 예로 들 수 있다.Therefore, recently, interest in natural food additives that benefit human health as a food additive or ingredient has emerged. With the westernization of diet, it is revealed that the main cause of various adult diseases is in the diet, and research is being conducted to find functional substances that improve the physiological functions of the human body from living organisms (animals, plants, microorganisms) and enzymes. Among them, glutaminase enzyme, which is known as a commercially important enzyme that can enhance the taste of food, is a representative example.

글루타미나제는 L-글루타민을 L-글루타민산염으로 탈아민화시키는 촉매역할을 하며, 식품에 첨가하였을 때 맛을 증진시키는 효과를 가지고(Hodson & Linden, Physiology & Behavior 89(5):711-717, 2006), 일반적으로 간장과 같은 발효식품에 맛을 제공하는 중요한 효소로 알려져 있다. 상기 글루타민산염의 소듐 염 성분은 음식에 첨가하였을 때 맛을 내는 역할을 하며, 효모나 곰팡이뿐만 아니라 박테리아를 포함한 미생물 어디에나 포함되어 있어, 발효식품의 첨가제로 널리 쓰인다(Naohisa M et al., J. Bioscience & Bioengineering, 2005). 글루타민산염 생성에 가장 큰 역할을 수행하는 글루타미나제는 대체로 온도나 열에 대한 안정성을 보이며, 염에 대한 내성이 높아 식품가공과정에서의 환경 변화 조건에 견딜 수 있기 때문에(Lapufade P et al., Appl Environ Microbiol 64:2485-2489, 1998) 식품첨가제로서 사용이 가능하다. 또한 아스파라기나제(asparaginase)와 결합하여 백혈병 치료에 효과적일 수 있다는 연구 결과도 나타나 있다.(Masuo N et al., Bioscience & Bioengineering, 2005). Glutaminase acts as a catalyst for the deamination of L-glutamine into L-glutamate and has a taste enhancing effect when added to foods (Hodson & Linden, Physiology & Behavior 89 (5): 711-717 , 2006), are generally known as important enzymes that provide taste to fermented foods such as soy. The sodium salt component of glutamate serves to taste when added to food, and is widely used in microorganisms including bacteria as well as yeast or mold, and is widely used as an additive in fermented foods (Naohisa M et al., J. Bioscience & Bioengineering, 2005). Glutaminase, which plays the largest role in the production of glutamate, is generally stable to temperature and heat, and has high salt resistance, which can withstand environmental changes in food processing (Lapufade P et al., Appl Environ Microbiol 64: 2485-2489, 1998). It has also been shown to be effective in treating leukemia in combination with asparaginase (Masuo N et al., Bioscience & Bioengineering, 2005).

인간의 구강계, 소화계 및 비뇨 생식계의 정상균총으로 서식하는 락토바실러스 속 유산균(Lactobacillus spp.)은 젖산을 생성하여 pH를 산성화시켜 병원성을 무력화시키며, 락토바실러스 속 유산균에 의해 생성된 항생물질인 박테리오신(bacterocin)은 여러 가지 병원성 균의 생육을 억제한다(Goossens D et al., Dig Dis Sci 37:44-50, 2005; Hiller SL et al., Clin Infect Dis 16:S273-281, 1991; Karine V et al., J Bacteriol 70:2057-2064, 2002; Ouwehand AC et al., Antonie van Leeuvenhoek 82:279-289, 2002). 이와 같은 특징을 갖는 락토바실러스 속 유산균은 인간과 동물의 식이요법 치료제와 정장제로 사용되는 프로바이오틱스(probiotics)로 많은 연구가 되어있다(Talarico TL et al., Antimicrob Agents Chemother 32:1854-1858, 1988; Wolf BW et al., Food Chem Toxicol 36:1085-1094, 1998).Lactobacillus spp., Which lives in the normal flora of the human oral, digestive and urogenital systems, produces lactic acid to acidify the pH to neutralize pathogenicity, and bacteriocin, an antibiotic produced by Lactobacillus lactic acid bacteria. (bacterocin) inhibits the growth of several pathogenic bacteria (Goossens D et al., Dig Dis Sci 37: 44-50, 2005; Hiller SL et al., Clin Infect Dis 16: S273-281, 1991; Karine V et al., J Bacteriol 70: 2057-2064, 2002; Ouwehand AC et al., Antonie van Leeuvenhoek 82: 279-289, 2002). Lactic acid bacteria of the genus Lactobacillus having such characteristics have been studied a lot of probiotics (probiotics) used as dietary treatments and formal dressings of humans and animals (Talarico TL et al., Antimicrob Agents Chemother 32: 1854-1858, 1988; Wolf BW et al., Food Chem Toxicol 36: 1085-1094, 1998).

프로바이오틱스 균주의 대표적인 예로, 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 에시도필러스(Lactobacillus acidophilus), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 불가리쿠스(Lactobacillus bulgaricus), 락토바실러스 람노수스(Lactobacillus rhamnosus) 및 락토바실러스 델브루에키이(Lactobacillus delbrueckii) 같은 몇몇 종은 염에 내성이 높고, 열에 대한 안정성도 높은 것으로 연구되었다(Erwin G et al., J Bacteriol 180:4718-4723, 1998; Jaya P et al., Appl Envir Microbiol 69:917-925,2003). Representative examples of probiotic strains include Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus helveticus, Lactobacillus bulgaricus and Lactobacillus bulgaricus. Some species, such as Lactobacillus rhamnosus and Lactobacillus delbrueckii, have been studied to be resistant to salts and to heat stability (Erwin G et al., J Bacteriol 180: 4718-4723, 1998; Jaya) P et al., Appl Envir Microbiol 69: 917-925,2003).

또한 상기 프로바이오틱스 균주 중 일부는 글루타미나제 활성을 나타내는 것이 알려져 있으며, 락토바실러스 루테리F275, 락토바실러스 존소니 (Lactobacillus johnsonii NCC533), 락토바실러스 개서리 (Lactobacillus gasseri LGAS0507) 등의 글루타미나제 유전자 서열이 공개되어 있다.In addition, some of the probiotic strains are known to exhibit glutaminase activity, and glutaminase gene sequences such as Lactobacillus luteri F275, Lactobacillus johnsonii NCC533, and Lactobacillus gasseri LGAS0507 Is open to the public.

그러나 상기 글루타미나제 유전자를 균주에 도입하여 글루타미나제 활성을 증가시키는 것과 관한 연구는 알려지지 아니한 실정이다. However, studies on increasing glutaminase activity by introducing the glutaminase gene into a strain are unknown.

이에 본 발명자들은 글루타미나제 활성을 증진시키는 방법에 대하여 연구, 노력한 결과 락토바실러스 루테리의 글루타미나제 유전자를 락토바실러스 속 특정 균주에 도입하면 우수한 글루타미나제 활성을 얻을 수 있음을 발견함으로써 본 발명을 완성하게 되었다. Therefore, the present inventors have studied and tried to improve the glutaminase activity, and found that by introducing the glutaminase gene of Lactobacillus luterie into a specific strain of Lactobacillus, excellent glutaminase activity can be obtained. The present invention has been completed.

따라서 본 발명은 락토바실러스 루테리의 글루타미나제 유전자가 도입된 락토바실러스 속 균주를 제공하는 것을 목적으로 한다. Accordingly, an object of the present invention is to provide a strain of the genus Lactobacillus into which the glutaminase gene of Lactobacillus luterie is introduced.

본 발명은 서열번호 1의 유전자가 도입된 락토바실러스 플란타룸 KLB 213-13(KCTC 18164P)을 특징으로 한다. The invention is characterized by Lactobacillus plantarum KLB 213-13 (KCTC 18164P) into which the gene of SEQ ID NO: 1 is introduced.

또한 본 발명은 서열번호 1의 유전자가 도입된 락토바실러스 파라카제이 KLB 58-7(수탁번호 KCTC 18163P)을 특징으로 한다. In addition, the present invention is characterized by Lactobacillus paracasei KLB 58-7 (Accession No. KCTC 18163P) into which the gene of SEQ ID NO: 1 is introduced.

또한 본 발명은 서열번호 1의 유전자를 포함하는 락토바실러스 속 균주의 형질전환용 벡터 pGlu-16를 또다른 특징으로 한다. In another aspect, the present invention is characterized by another vector pGlu-16 for transformation of the genus Lactobacillus strain comprising the gene of SEQ ID NO: 1.

본 발명에 의하여 높은 글루타미나제 활성을 가지는 락토바실러스 속 균주를 천연 식품 첨가제로 사용하여 글루타민으로부터 글루타민산염을 생산할 수 있으며, 이는 기존의 인공 식품 첨가제에 의한 부작용이나 병적 증세를 회피할 수 있다. According to the present invention, glutamate can be produced from glutamine by using a strain of the genus Lactobacillus having high glutaminase activity as a natural food additive, which can avoid side effects or pathological symptoms caused by existing artificial food additives.

본 발명은 서열번호 1의 유전자가 도입된 락토바실러스 플란타룸 KLB 213-13 (KCTC 18164P)을 특징으로 한다. The invention is characterized by Lactobacillus plantarum KLB 213-13 (KCTC 18164P) into which the gene of SEQ ID NO: 1 is introduced.

또한 본 발명은 서열번호 1의 유전자가 도입된 락토바실러스 파라카제이 KLB 58-7(KCTC 18163P)을 특징으로 한다. In another aspect, the present invention is characterized by Lactobacillus paracasei KLB 58-7 (KCTC 18163P) in which the gene of SEQ ID NO: 1 is introduced.

상기 서열번호 1의 유전자의 길이는 1293 bp 에 해당하고, 상기 유전자 내에 존재하는 글루타미나제 유전자는 락토바실러스 루테리 F275의 유전자 서열에서 228 ~ 1167번째 위치에 존재하며, 그 길이는 939 bp에 해당한다. The length of the gene of SEQ ID NO: 1 corresponds to 1293 bp, and the glutaminase gene present in the gene is present at positions 228 to 1167 in the gene sequence of Lactobacillus luteri F275, and its length corresponds to 939 bp. do.

또한 상기 서열번호 1의 유전자는 상기 서열번호 1뿐만 아니라 상기 서열번호 1의 일부 염기가 치환, 결실 또는 부가된 변형서열로서 글루타미나제 활성을 나타내는 염기서열을 포함한다.In addition, the gene of SEQ ID NO: 1 includes a base sequence that exhibits glutaminase activity as a modified sequence in which not only SEQ ID NO: 1 but also some bases of SEQ ID NO: 1 are substituted, deleted or added.

상기 서열번호 1의 유전자가 도입되어 형질 전환된 락토바실러스 플란타룸 KLB 213-13은 KCTC 에 유전자 수탁 번호 KCTC 18164P로 2009년 6월 19일에 기탁되었으며, 서열번호 1의 유전자가 도입되어 형질 전환된 락토바실러스 파라카제이 KLB 58-7은 KCTC 에 유전자 수탁 번호 KCTC 18163P 로 2009 년 6월 19일에 기탁되었다. The Lactobacillus plantarum KLB 213-13 transformed by introducing the gene of SEQ ID NO: 1 was deposited on June 19, 2009 with the accession number KCTC 18164P to KCTC, and the gene of SEQ ID NO: 1 was introduced and transformed. Lactobacillus paracasei KLB 58-7 was deposited with KCTC on accession number KCTC 18163P on June 19, 2009.

또한 본 발명은 서열번호 1의 유전자를 포함하는 락토바실러스 속 균주의 형질전환용 벡터 pGlu-16를 특징으로 한다. The present invention also features a vector pGlu-16 for transformation of a strain of the genus Lactobacillus comprising the gene of SEQ ID NO: 1.

이하, 본 발명을 하기 실시예에 의해 더욱 상세히 설명하고자 한다. 하기 실시예는 본 발명을 예시하기 위한 목적으로 주어진 것이며 본 발명의 범위를 제한하는 것은 아니다.Hereinafter, the present invention will be described in more detail by the following examples. The following examples are given for the purpose of illustrating the invention and do not limit the scope of the invention.

[[ 실시예Example ]]

1. 글루타미나제 유전자의 클로닝1. Cloning of the Glutaminase Gene

미국 국립생물정보센터(NCBI)(www.ncbi.nlm.nih.gov)의 뉴클레오티드 검색을 통하여 락토바실러스 루테리 F275(NC009513)의 유전자 서열을 바탕으로, 글루타미나제 유전자의 증폭을 위한 정방향 프라이머 5′- AGT CAC GAG TGA CTT CTG - 3′(서열번호 2) 및 역방향 프라이머 5′- AGC GGT GGC AAA GTA GTC - 3′(서열번호 3)을 설계하였다. 그리고 락토바실러스 루테리(Lactobacillus reuteri) KCTC 3594로부터 서열번호 1의 게노믹(genomic) DNA를 추출하고(도 1), 이를 주형으로 하여 상기 프라이머를 사용한 PCR을 수행하였고, 이를 통하여 상기 서열번호 1의 유전자를 증폭하였다.Forward primer 5 for amplification of the glutaminase gene, based on the gene sequence of Lactobacillus luteri F275 (NC009513) through nucleotide search by the National Institute of Biological Information (NCBI) (www.ncbi.nlm.nih.gov) ′-AGT CAC GAG TGA CTT CTG-3 ′ (SEQ ID NO: 2) and reverse primer 5′- AGC GGT GGC AAA GTA GTC-3 ′ (SEQ ID NO: 3) were designed. And genomic DNA of SEQ ID NO: 1 was extracted from Lactobacillus reuteri KCTC 3594 (FIG. 1), PCR was performed using the primers as a template, and the gene of SEQ ID NO: 1 was used. Was amplified.

2. 글루타미나제 유전자 도입용 벡터 제작2. Preparation of vector for introduction of glutaminase gene

상기 증폭된 서열번호 1의 유전자를 pGEM-T easy 벡터(Promega 사)에 삽입하고, 이를 pL3594로 명명하였다. 이후 상기 pL3594 와 대장균-락토바실러스 셔틀 벡터(E.coli-Lactobacillus shuttle vector)인 pTRKL2를 라이게이션 하여 7.5kb 의 플라스미드 pGlu-16을 제조하였다. The amplified gene of SEQ ID NO: 1 was inserted into a pGEM-T easy vector (Promega), which was named pL3594. After pL3594 and pTRKL2, which is an E. coli - Lactobacillus shuttle vector, was ligated to prepare plasmid pGlu-16 of 7.5 kb.

3. 락토바실러스 플란타룸의 형질전환3. Transformation of Lactobacillus plantarum

락토바실러스 플란타룸 KLB 213 균주를 15 mL 플라스크 중의 1 중량% 글라이신이 포함된 5 mL MRS 배지(Difco, West Molesey)에 접종하여 37 ℃, 정치 조건에서 3 시간 배양한 뒤, 8,000 rpm에서 원심분리 후 1 mL SM 버퍼에 현탁한 뒤 100 ㎕씩 분주하여 반응능 세포(competant cell)를 얻었다. Lactobacillus plantarum KLB 213 strain was inoculated in 5 mL MRS medium containing 1% by weight glycine in 15 mL flasks (Difco, West Molesey), incubated for 3 hours at 37 ° C and stationary conditions, followed by centrifugation at 8,000 rpm. After suspension in 1 mL SM buffer and 100 ㎕ were dispensed to obtain a competent cell (competant cell).

위와 같이 만들어진 세포에 상기 실시예 2의 글루타미나제 유전자 도입용 벡터 pGlu-16 1 ㎍을 상기 반응능 세포에 첨가한 뒤 얼음에 보관 중인 2 mm 전기천공 큐벳에 넣고 1.2 kV, 2 ms 로 전기천공한 뒤 MRS를 200 ㎕ 섞어주어 37 ℃ 에서 3시간 배양한 다음 에리스로마이신 5㎍/ml 함유 MRS 플레이트에 도말하였다. 생성된 콜로니는 에리스로마이신 5 ㎍/ml 함유 MRS 플레이트에서 다시 한번 확인하였다.1 μg of the glutaminase gene introduction vector pGlu-16 of Example 2 was added to the reactive cells, and placed in a 2 mm electroporation cuvette stored in ice, and then subjected to 1.2 kV, 2 ms. After puncture, 200 μl of MRS was mixed and incubated at 37 ° C. for 3 hours, and then plated on a MRS plate containing 5 μg / ml of erythromycin. The resulting colonies were once again confirmed on MRS plates containing 5 μg / ml of erythromycin.

4. 락토바실러스 파라카제이의 형질전환4. Transformation of Lactobacillus paracasei

락토바실러스 파라카제이 KLB 58 균주를 15 mL 플라스크 중의 1 중량% 글라이신이 포함된 5 mL MRS 배지(Difco, West Molesey)에 접종하여 37 ℃, 정치 조건에서 3 시간 배양한 뒤, 8,000 rpm에서 원심분리 이 후 1 mL SM 버퍼에 현탁한 뒤 100 ㎕씩 분주하여 반응능 세포(competant cell)를 얻었다. Lactobacillus paracasei KLB 58 strains were inoculated in 5 mL MRS medium containing 1% by weight glycine in 15 mL flasks (Difco, West Molesey), incubated at 37 ° C. for 3 hours, and then centrifuged at 8,000 rpm. Thereafter, the cells were suspended in 1 mL SM buffer and dispensed into 100 μl to obtain competent cells.

위와 같이 만들어진 반응능 세포에 상기 실시예 2의 글루타미나제 유전자 도입용 벡터 pGlu-16 1 ㎍을 첨가한 뒤 얼음에 보관 중인 2 mm 전기천공 큐벳에 넣고 1.2 kV, 2 ms 로 전기천공한 뒤 MRS를 200 ㎕ 섞어주어 37 ℃ 에서 3시간 배양한 다음 에리스로마이신 5㎍/ml 함유 MRS 플레이트에 도말하였다. 생성된 콜로니는 에리스로마이신 5㎍/ml 함유 MRS 플레이트에서 다시 한번 확인했다.After adding 1 ㎍ of the glutaminase gene introduction vector pGlu-16 of Example 2 to the reactive cell prepared as described above, put it in a 2 mm electroporation cuvette stored in ice and electroporated at 1.2 kV, 2 ms. 200 μl of MRS was mixed and incubated at 37 ° C. for 3 hours, and then plated on an MRS plate containing 5 μg / ml of erythromycin. The resulting colonies were once again confirmed on MRS plates containing 5 μg / ml of erythromycin.

5. 균주 내 유전자 도입 여부 확인5. Check whether the gene is introduced into the strain

상기 실시예 3 및 4에서 얻은 형질전환 락토바실러스 균주로부터 게노믹 DNA를 추출하였다. 상기 각각의 게노믹 DNA를 주형으로 하여 상기 서열번호 1의 유전자의 증폭을 위한 서열번호 2 및 3의 프라이머쌍, 및 에리스로마이신 저항 유전자의 증폭을 위한 정방향 프라이머 5′- GAA ATT GGA ACA GGT AAA GG - 3′(서열번호 4) 및 역방향 프라이머 5′- GAT ATT CTC TGA CCC AT - 3′(서열번호 5)를 사용한 각각의 PCR을 수행하여 유전자의 삽입 여부를 최종 확인하였다. Genomic DNA was extracted from the transformed Lactobacillus strains obtained in Examples 3 and 4. Primer pairs of SEQ ID NOs: 2 and 3 for amplification of the gene of SEQ ID NO: 1 using each genomic DNA as a template, and forward primers for amplification of the erythromycin resistance gene 5′- GAA ATT GGA ACA GGT AAA GG Each PCR was performed using 3 ′ (SEQ ID NO: 4) and reverse primer 5′- GAT ATT CTC TGA CCC AT-3 ′ (SEQ ID NO: 5) to finally confirm whether the gene was inserted.

6. 글루타미나제 활성의 측정6. Measurement of Glutaminase Activity

락토바실러스 루테리 KCTC 3594, 락토바실러스 플란타룸 KLB 213, 락토바실러스 파라카제이 KLB 58, 및 상기 형질 전환된 실시예 3의 락토바실러스 플란타룸 KLB 213-13, 실시예 4의 락토바실러스 파라카제이 KLB 58-7을 37 ℃ 혐기성 조건에서 1.5% 한천 도말된 에리스로마이신 5 ㎍/ml 함유 MRS 평판 배지에서 배양하였다. 상기 MRS는 1 L를 기준으로 글루코오스 20 g, 펩톤 NO.3 10 g, 육즙 10 g, 효모추출물 5 g, 아세트산나트륨 5 g, 인산일수소칼륨(K2HPO4) 2 g, 트윈 80 1 g, 미량 염류 용액(CaCl2 5 g, FeSO4 125 mg, CaSO4 75 mg, MnSO4 4.3 mg, ZnSO4 108 mg, Na2MoO4 ? 2H20 125 mg, 니트릴아세테이트 7 g) 2 mL를 포함하도록 하였다. Lactobacillus luteri KCTC 3594, Lactobacillus plantarum KLB 213, Lactobacillus paracasei KLB 58, and the transformed Lactobacillus plantarum KLB 213-13, Lactobacillus paracaze of Example 4 KLB 58-7 was incubated in MRS plate medium containing 5 μg / ml of 1.5% agar smeared erythromycin at 37 ° C. anaerobic conditions. The MRS is based on 20 g of glucose, 10 g of peptone NO.3, 10 g of gravy, 5 g of yeast extract, 5 g of sodium acetate, 2 g of potassium dihydrogen phosphate (K 2 HPO 4 ), and twin 80 1 g. , trace salts solution (CaCl 2 5 g, FeSO 4 125 mg, CaSO 4 75 mg, MnSO 4 4.3 mg, ZnSO 4 108 mg, Na 2 MoO 4? 2H 2 0 125 mg, nitrile acetate 7 g) containing 2 mL of It was made.

MRS 한천 평판 배지 위의 콜로니는 에리스로마이신 5 ㎍/㎖ 이 포함된 MRS (broth) 5 mL에 옮겨지고 37 ℃에서 24 ~ 48 시간 동안 배양하였다. 상기 배양액을 5분간 8000 x g에서 원심분리하여 배양된 세포를 얻었다. Colonies on MRS agar plate medium were transferred to 5 mL of MRS (broth) containing 5 μg / ml of erythromycin and incubated at 37 ° C. for 24 to 48 hours. The culture was centrifuged at 8000 x g for 5 minutes to obtain cultured cells.

잔여 성분을 제거하기 위하여 TE 완충 용액(50 mM Tris-HCl 및 5 mM EDTA, pH 7.5)으로 2회 세척한 뒤 TE 완충 용액 1 ml에 재현탁시키고 1분간 소니케이션(sonication)에 의하여 균질화시켰다. To remove residual components, washed twice with TE buffer solution (50 mM Tris-HCl and 5 mM EDTA, pH 7.5) and then resuspended in 1 ml of TE buffer solution and homogenized by sonication for 1 minute.

이후 각각의 세포의 총 단백질의 농도는 소의 혈청 알부민을 사용한 브래드포드(Bradford) 방법에 의하여 측정되었다. The total protein concentration of each cell was then measured by the Bradford method using bovine serum albumin.

또한, 37℃에서 5분 동안 2 중량% L-글루타민 용액과 100mM Tris-HCl 완충 용액(pH 7.5)이 혼합된 용액을 평형시킨 후, 상기 각 균질화된 세포 0.1 mL 를 첨가하고 10분간 37℃에서 반응시켰다. 반응물을 3분간 가열하여 반응을 중지시킨 후, 5분간 8000 x g에서 원심분리하고 상등액 50㎕를 취하여 하이드록실아민 완충 용액(0.25M 하이드록실 아민 및 20mM EDTA, pH 8.0) 1 mL, 10 mM NAD+ 용액 0.5 mL, 1 mL 증류수 및 20 U/ml 글루탐산탈수소효소(glutamate dehydrogenase, GLDH) 혼합물에 첨가하였다. 37℃에서 30 분간 반응시킨 후 340 nm 파장에서 흡광도를 측 정하였다. 글루타미나제 활성에서 1 U(unit)은 37℃에서 1분간 1μmol 의 NADH를 생성하기 위하여 요구되는 글루타미나제의 양으로 정의된다. In addition, after equilibrating the mixed solution of 2 wt% L-glutamine solution and 100 mM Tris-HCl buffer solution (pH 7.5) for 5 minutes at 37 ℃, 0.1 mL of each of the homogenized cells was added and 10 minutes at 37 ℃ Reacted. The reaction was stopped by heating the reaction for 3 minutes, then centrifuged at 8000 xg for 5 minutes and 50 μl of supernatant was added to 1 mL of hydroxylamine buffer solution (0.25 M hydroxyl amine and 20 mM EDTA, pH 8.0), 10 mM NAD + 0.5 mL of solution, 1 mL distilled water and 20 U / ml glutamate dehydrogenase (GLDH) mixture were added. After reacting at 37 ° C. for 30 minutes, absorbance was measured at 340 nm. 1 U (unit) in glutaminase activity is defined as the amount of glutaminase required to produce 1 μmol NADH for 1 minute at 37 ° C.

상기 측정된 각 세포의 총 단백질, 글루타미나제 활성을 하기 표 1에 나타내었고, 단위 활성을 비교한 그래프를 도 2에 나타내었다. The total protein and glutaminase activity of each cell measured are shown in Table 1 below, and a graph comparing unit activity is shown in FIG. 2.

세포cell 총 단백질 (mg)Total protein (mg) 총 활성(U)Total active (U) 단위 활성 (U/mg)Unit activity (U / mg) 락토바실러스 루테리 KCTC 3594Lactobacillus luster KCTC 3594 9.039.03 4.6604.660 0.5160.516 락토바실러스 플란타룸 KLB 213Lactobacillus plantarum KLB 213 5.725.72 1.2061.206 0.2100.210 락토바실러스 파라카제이 KLB 58Lactobacillus paracazei KLB 58 5.825.82 -- -- 형질전환된 락토바실러스 플란타룸 KLB 213-13 (실시예3)Transformed Lactobacillus plantarum KLB 213-13 (Example 3) 5.725.72 4.4864.486 0.7840.784 형질전환된 락토바실러스 파라카제이 KLB 58-7 (실시예4)Transformed Lactobacillus paracasei KLB 58-7 (Example 4) 1.771.77 1.2061.206 0.2490.249

상기 표 1에서 보는 바와 같이 락토바실러스 플란타룸 KLB 213은 락토바실러스 루테리 KCTC 3594 에 비하여 1/2 정도의 글루타미나제 활성을 나타내었으나, 실시예 3의 형질전환된 락토바실러스 플란타룸 KLB 213-13 은 락토바실러스 루테리 KCTC 3594의 1.5 배 이상의 활성을 나타내었다. As shown in Table 1, Lactobacillus plantarum KLB 213 showed about 1/2 glutaminase activity as compared to Lactobacillus luteri KCTC 3594, but the transformed Lactobacillus plantarum KLB 213 of Example 3 -13 showed more than 1.5-fold activity of the Lactobacillus luteri KCTC 3594.

그리고 락토바실러스 파라카제이 KLB 58은 글루타미나제 활성을 나타내지 아니하나, 실시예 4의 형질전환된 락토바실러스 파라카제이 KLB 58-7은 0.2 U/mg 이상의 활성을 나타내었다. And Lactobacillus paracasei KLB 58 did not exhibit glutaminase activity, but transformed Lactobacillus paracasei KLB 58-7 of Example 4 showed 0.2 U / mg or more activity.

따라서 서열번호 1의 유전자가 도입된 락토바실러스 플란타룸 KLB 213-13 이 형질전환되지 아니한 야생형(wild type) 락토바실러스 플란타룸 KLB 213 에 비하여 현저하게 우수한 글루타미나제 활성을 나타내는 것을 확인할 수 있었다. Therefore, it was confirmed that Lactobacillus plantarum KLB 213-13 into which the gene of SEQ ID NO: 1 was introduced showed significantly better glutaminase activity than wild type Lactobacillus plantarum KLB 213 which was not transformed. there was.

도 1은 서열번호 1의 유전자 서열을 나타낸 것이다. 노란색으로 나타낸 부분 중 ATG는 개시코돈을, TAA는 종결코돈을 나타낸다. Figure 1 shows the gene sequence of SEQ ID NO: 1. ATG represents the start codon and TAA represents the stop codon.

도 2는 락토바실러스 루테리 KCTC 3594, 락토바실러스 플란타룸 KLB 213 및 락토바실러스 파라카제이 KLB 58 의 야생형과 본 발명에 따라 형질전환된 락토바실러스 플란타룸 KLB 213 및 락토바실러스 파라카제이 KLB 58의 글루타미나제 활성을 비교한 그래프이다. FIG. 2 shows wild-types of Lactobacillus luteri KCTC 3594, Lactobacillus plantarum KLB 213 and Lactobacillus paracaze KLB 58 and Lactobacillus plantarum KLB 213 and Lactobacillus paracaze KLB 58 transformed according to the present invention. It is a graph comparing glutaminase activity.

<110> INHA-INDUSTRY PARTNERSHIP INSTITUTE <120> Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri <160> 5 <170> KopatentIn 1.71 <210> 1 <211> 1293 <212> DNA <213> Lactobacillus reuteri <400> 1 agtcacgagt gacttctgtc tcgctcccat ttcgttatct ttttttataa aaatatttat 60 tctaattatt tgatttattt ataatatatt tgttgcgact attacgatga ttagtatctg 120 agaagatgag ctcatgtaga tattaggcta ttatttcatc atgcaaatta agtgtaaagg 180 ggggctaatt tttcttgttt ggtacttgag gagctgcagg gttatttatg ccttgtgtga 240 gagaggtttt gacgatgcaa aaattagagc aattgattga taaaaacttt gctgaaacag 300 ctcatggtaa ggttgcaaac tatattccga tattaggaat tgttgatccg caacaactgg 360 gcattgccat ttatgacgtt gacgaggacg aaattgggac cgctggaatg gcaggaacgc 420 gatttgcgat cgagagtatt gcgaaggtca taactttaat attaacgatc aagagattag 480 gacataagcg cgtcttagca gaactagaaa atggttcggc agattatagc ctaagttcgg 540 tactattgga tgacgagtta accgagcagg tccaccgggt aaattacctt aataattcct 600 ccgctttgtt aacgacagcc ttaattgacc agttgatggg gcagaatagt tttaatgccc 660 ttctcggttt ctgccgtgag atctgcaatg acccatgcat tagcttgaat gagcgtttat 720 ttcggtcagc aattatgaat gataaagata ttcatgcact ggcttactat atgaaagata 780 aagatatttt agagactgtt gatcaaacat tgataactta ttttatgcaa agctcaatga 840 tggtgacatc acagagtctt gctaacctag gagcagtctt ggcaaatgat ggaattaaac 900 cttgggataa tgagcgtctt attagccatg aagataacga gttggtaaag aaattgctaa 960 caacagttgg ttcgtttgaa gaatcaaaag aatacacaat taaaattgaa ctccctatta 1020 aaagtggtac tggcggcggc ttattggctt gtgccccgca aaaatgtggt attggtattt 1080 ttagtccagc tcttgatcaa catggcaata gtttggcagg aatgagttta ttacaagatg 1140 ttgttgatca attagaatta gtagtttaat cataaccacc cgtcaaacgg gtggtttgca 1200 catcggctat aagccgataa taaaagccgg cgtctcaagg cgctggcttt cgctttgctc 1260 aagccaaaat gctctgacta ctttgccacc gct 1293 <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Forward primer(Glutaminase) <400> 2 agtcacgagt gacttctg 18 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer(Glutaminase) <400> 3 agcggtggca aagtagtc 18 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer(Erythromycin) <400> 4 gaaattggaa caggtaaagg 20 <210> 5 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer(Erythromycin) <400> 5 gatattctct gacccat 17 <110> INHA-INDUSTRY PARTNERSHIP INSTITUTE <120> Lactobacillus genus microorganism having the glutaminase gene of          Lactobacillus reuteri <160> 5 <170> KopatentIn 1.71 <210> 1 <211> 1293 <212> DNA <213> Lactobacillus reuteri <400> 1 agtcacgagt gacttctgtc tcgctcccat ttcgttatct ttttttataa aaatatttat 60 tctaattatt tgatttattt ataatatatt tgttgcgact attacgatga ttagtatctg 120 agaagatgag ctcatgtaga tattaggcta ttatttcatc atgcaaatta agtgtaaagg 180 ggggctaatt tttcttgttt ggtacttgag gagctgcagg gttatttatg ccttgtgtga 240 gagaggtttt gacgatgcaa aaattagagc aattgattga taaaaacttt gctgaaacag 300 ctcatggtaa ggttgcaaac tatattccga tattaggaat tgttgatccg caacaactgg 360 gcattgccat ttatgacgtt gacgaggacg aaattgggac cgctggaatg gcaggaacgc 420 gatttgcgat cgagagtatt gcgaaggtca taactttaat attaacgatc aagagattag 480 gacataagcg cgtcttagca gaactagaaa atggttcggc agattatagc ctaagttcgg 540 tactattgga tgacgagtta accgagcagg tccaccgggt aaattacctt aataattcct 600 ccgctttgtt aacgacagcc ttaattgacc agttgatggg gcagaatagt tttaatgccc 660 ttctcggttt ctgccgtgag atctgcaatg acccatgcat tagcttgaat gagcgtttat 720 ttcggtcagc aattatgaat gataaagata ttcatgcact ggcttactat atgaaagata 780 aagatatttt agagactgtt gatcaaacat tgataactta ttttatgcaa agctcaatga 840 tggtgacatc acagagtctt gctaacctag gagcagtctt ggcaaatgat ggaattaaac 900 cttgggataa tgagcgtctt attagccatg aagataacga gttggtaaag aaattgctaa 960 caacagttgg ttcgtttgaa gaatcaaaag aatacacaat taaaattgaa ctccctatta 1020 aaagtggtac tggcggcggc ttattggctt gtgccccgca aaaatgtggt attggtattt 1080 ttagtccagc tcttgatcaa catggcaata gtttggcagg aatgagttta ttacaagatg 1140 ttgttgatca attagaatta gtagtttaat cataaccacc cgtcaaacgg gtggtttgca 1200 catcggctat aagccgataa taaaagccgg cgtctcaagg cgctggcttt cgctttgctc 1260 aagccaaaat gctctgacta ctttgccacc gct 1293 <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Forward primer (Glutaminase) <400> 2 agtcacgagt gacttctg 18 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> Reverse primer (glutaminase) <400> 3 agcggtggca aagtagtc 18 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer (Erythromycin) <400> 4 gaaattggaa caggtaaagg 20 <210> 5 <211> 17 <212> DNA <213> Artificial Sequence <220> Reverse primer (Erythromycin) <400> 5 gatattctct gacccat 17  

Claims (3)

서열번호 1의 유전자가 도입된 락토바실러스 플란타룸 KLB 213-13 (수탁번호 KCTC 18164P).Lactobacillus plantarum KLB 213-13 (accession number KCTC 18164P) into which the gene of SEQ ID NO: 1 was introduced. 서열번호 1의 유전자가 도입된 락토바실러스 파라카제이 KLB 58-7 (수탁번호 KCTC 18163P).Lactobacillus paracasei KLB 58-7 (accession number KCTC 18163P) into which the gene of SEQ ID NO: 1 was introduced. 삭제delete
KR1020090087728A 2009-09-16 2009-09-16 Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri KR101127164B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020090087728A KR101127164B1 (en) 2009-09-16 2009-09-16 Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090087728A KR101127164B1 (en) 2009-09-16 2009-09-16 Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri

Publications (2)

Publication Number Publication Date
KR20110029876A KR20110029876A (en) 2011-03-23
KR101127164B1 true KR101127164B1 (en) 2012-03-20

Family

ID=43935705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090087728A KR101127164B1 (en) 2009-09-16 2009-09-16 Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri

Country Status (1)

Country Link
KR (1) KR101127164B1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100635450B1 (en) 2005-01-11 2006-10-17 고려대학교 산학협력단 Transformation method and expression vector for Lactobacillus species
KR20070038235A (en) * 2005-10-05 2007-04-10 씨제이 주식회사 A vector for the lactobacillus genus microorgansim containing ldh gene, lactobacillus genus microorgansim having integrated ldh gene in its chromosome, method of selecting the microorgansim and a method of producing l-lactic acid using the microorgansim

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100635450B1 (en) 2005-01-11 2006-10-17 고려대학교 산학협력단 Transformation method and expression vector for Lactobacillus species
KR20070038235A (en) * 2005-10-05 2007-04-10 씨제이 주식회사 A vector for the lactobacillus genus microorgansim containing ldh gene, lactobacillus genus microorgansim having integrated ldh gene in its chromosome, method of selecting the microorgansim and a method of producing l-lactic acid using the microorgansim

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Genbank accession number : AP007281 (2008.09.04)*
Gene, Vol.137, pp.227-231(1993.12.31.)*

Also Published As

Publication number Publication date
KR20110029876A (en) 2011-03-23

Similar Documents

Publication Publication Date Title
Lee et al. Probiotic properties of Weissella strains isolated from human faeces
Koll et al. Characterization of oral lactobacilli as potential probiotics for oral health
TWI379003B (en)
JP5875975B2 (en) Probiotic microorganisms isolated from donkey milk
An et al. Coexpression of the superoxide dismutase and the catalase provides remarkable oxidative stress resistance in Lactobacillus rhamnosus
KR20170015685A (en) Bacillus subtilis SCM146 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce, antioxidant activity and enzyme secretion activity, and not producing biogenic amine and uses thereof
Yin et al. Isolation and identification of the dominant Lactobacillus in gut and faeces of pigs using carbohydrate fermentation and 16S rDNA analysis
Todorov et al. Characterization of bacteriocin HV219, produced by Lactococcus lactis subsp. lactis HV219 isolated from human vaginal secretions
Ishida et al. Identification and characterization of lactococcal and Acetobacter strains isolated from traditional Caucasusian fermented milk
KR101473146B1 (en) Composition for preventing or treating irritable bowel syndrome
EP3092320B1 (en) New strains of the genus lactobacillus and use thereof
Sen et al. Molecular characterization and in vitro analyses of a sporogenous bacterium with potential probiotic properties
KR100543115B1 (en) Lactic acid bacteria having high alcohol dehydrogenase and acetaldehyde dehydrogenase activity, and metabolize ethanol and acetaldehyde
KR100240687B1 (en) Lactobacillus acidophilus ky 2104 and its uses
KR100921697B1 (en) Method for using high osmotic pressure tolerant strain as natural flavor
KR101127164B1 (en) Lactobacillus genus microorganism having the glutaminase gene of Lactobacillus reuteri
KR100868777B1 (en) Food composition with Bifidobacterium adolescentis to utilize RS-3 type resistant starch
KR101473147B1 (en) Composition for preventing or treating irritable bowel syndrome
KR101453982B1 (en) Composition for preventing or treating irritable bowel syndrome
KR20060059588A (en) Lactic acid bacteria degrading alcohol and acetaldehyde
KR101726207B1 (en) --glucosidase LT19-2 [KCTC18497P]Novel Bifidobacterium animalis LT19-2 strain[KCTC18497P] having excellent -glucosidase activity
HWAN et al. Characterization of the $\alpha $-Galactosidase Gene from Leuconostoc mesenteroides SY1
AU754020B2 (en) Chemoprotective bacterial strains
KR100715730B1 (en) 24A novel Bifidobacterium longum A24 with anti-bacterial activity against toxigenic pathogens
KR20150088588A (en) Novel Gamma-Amino Butyric Acid Producing Strain of Lactobacillus Brevis CFM11 and Use of the Same

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20141204

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20160113

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20161220

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20171213

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20200227

Year of fee payment: 9